Janssen Loses La. Appeal Of $258M Risperdal Verdict
The three-judge panel rejected Janssen Pharmaceuticals Inc.’s arguments that the lower trial court denied it due process of law by allowing the state attorney general to pursue claims and penalties for alleged regulatory violations with insufficient evidence.
The panel also rejected Janssen’s...
To view the full article, register now.